BACE1 and Alzheimer disease: In this study, we pursued a combined computational and experimental approach to evaluate the propensity of CBDA and CBGA to act as MTDL agents against molecular targets relevant to AD, such as AChE, BuChE, and BACE‐1 enzymes.